8-K: ZEO ScientifiX Partners with A4M for Longevity Education

ZEO ScientifiX announced its role as the official educational partner for regenerative medicine with the American Academy of Anti-Aging Medicine (A4M) at Longevity SpringFest 2026.

Summary

• ZEO ScientifiX has been named the official educational partner for regenerative medicine with the American Academy of Anti-Aging Medicine (A4M) for Longevity SpringFest 2026.
• The company will lead a full-day Masterclass on regenerative and longevity medicine on April 9, 2026, in West Palm Beach, Florida.
• This partnership grants ZEO direct access to A4M's extensive network of 26,000 physicians and healthcare practitioners across more than 120 nations.
• The Masterclass will provide evidence-based training for advanced practitioners, covering scientific foundations, clinical integration, and regulatory compliance in regenerative medicine.
• ZEO's collaboration with A4M positions it alongside other industry leaders like Niagen Bioscience (NASDAQ: NAGE) and InBody (KRX: 041830) within the A4M educational network.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development, significantly enhancing ZEO's market presence, credibility, and access to a crucial network of healthcare professionals in a high-growth industry.

Positives

• Secured a significant partnership as the official educational partner for regenerative medicine with the American Academy of Anti-Aging Medicine (A4M).
• Gains direct access to A4M's global network of 26,000 physicians and healthcare practitioners from over 120 nations, enhancing market reach and influence.
• The partnership places ZEO alongside established public companies like Niagen Bioscience (NASDAQ: NAGE) and InBody (KRX: 041830) within a prestigious educational network.
• Opportunity to lead a specialized, full-day Masterclass, demonstrating expertise and setting industry standards in regenerative and longevity medicine.
• Operating in the growing $29.9 billion longevity therapy market.

Risks

• Forward-looking statements involve known and unknown risks and uncertainties, and actual results could vary dramatically from expectations.
• The company disclaims any duty to update information in the press release, meaning future developments may not be immediately disclosed.

Future Outlook

The company believes that the expectations reflected in its forward-looking statements are reasonable, though actual results could vary dramatically due to inherent assumptions, risks, and uncertainties. ZEO has no intention and specifically disclaims any duty to update the information in this press release.

Management Comments

• "We are incredibly excited to bring this level of specialized physician education to West Palm Beach." Dr. George C. Shapiro MD, Chief Medical Officer of ZEO.
• "By modeling this Masterclass after A4M’s renowned Professional Medical Education series, ZEO is helping set a new standard for how regenerative medicine is taught and implemented." Dr. George C. Shapiro MD, Chief Medical Officer of ZEO.
• "As Chair of the educational session, my goal is to ensure clinicians leave with a rigorous, evidence-based framework to safely and effectively lead the next wave of regenerative and longevity medicine." Dr. George C. Shapiro MD, Chief Medical Officer of ZEO.

Industry Context

StockSavvy.ai notes that ZEO ScientifiX's partnership with A4M positions it strategically within the rapidly expanding $29.9 billion longevity therapy market. This collaboration aligns ZEO with established industry players like Niagen Bioscience and InBody, leveraging a respected educational network to enhance its visibility and credibility among healthcare practitioners in the regenerative medicine space.

Comparison to Industry Standards

• ZEO's partnership with A4M places it alongside NASDAQ-listed Niagen Bioscience (NAGE) and KRX-listed InBody (041830) as leaders in A4M's educational global practitioner network.
• The Masterclass is modeled after A4M's prestigious Professional Medical Education (PME) series, indicating a commitment to high-quality, evidence-based training comparable to leading industry standards.
• The company operates out of Nova Southeastern University's $100 Million Center of Collaborative Research, suggesting access to advanced facilities and research capabilities.

Stakeholder Impact

• Shareholders: Potential for increased company visibility, market credibility, and growth opportunities in the longevity therapy market, which could positively impact share value.
• Employees: Enhanced professional development opportunities and a strengthened company profile, potentially attracting top talent.
• Customers (Physicians/Practitioners): Access to specialized, evidence-based training in regenerative and longevity medicine, improving their clinical practice.
• A4M: Strengthens A4M's educational offerings by partnering with a clinical-stage biotechnology company specializing in regenerative biologics.

Next Steps

• Conduct the full-day Masterclass on regenerative and longevity medicine on April 9, 2026.
• Continue research, development, and manufacturing of regenerative biologics.

Key Dates

Recommendation

The strategic partnership with A4M, a respected medical academy, significantly enhances ZEO ScientifiX's credibility and market reach within the rapidly growing $29.9 billion longevity therapy market. Gaining direct access to 26,000 physicians and healthcare practitioners provides a substantial platform for education and potential adoption of ZEO's regenerative biologics. This positions the company favorably alongside other established public companies in the A4M network, suggesting strong growth potential and increased investor confidence.

Keywords

regenerative medicine, longevity, biotechnology, A4M, medical education, clinical-stage, biologics, healthcare, ZEOX, anti-aging